CHICAGO ( TheStreet) --Welcome to TheStreet's live-blog coverage of the American Society of Clinical Oncology (ASCO) annual meeting. It's Sunday, the second full day of data presentations at the largest annual gathering of cancer drug researchers in the world.
On the schedule for today: ASCO's big plenary session, highlighting some of the most newsworthy clinical data at the conference. Roche (RHHBY) and ImmunoGen (IMGN - Get Report) are in the plenary spotlight this year with data from the phase III study of T-DM1 in breast cancer. Also sharing the plenary stage is a study combining Roche's Rituxan with Teva's (TEVA) Treanda in lymphoma.
>To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: firstname.lastname@example.org. Follow TheStreet on Twitter and become a fan on Facebook.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts